A Phase 2 interventional study of Asimadoline and Placebo in Post-Operative Ileus, sponsored by Tioga Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-01-06.
Sponsored by Tioga Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Ileus with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Ileus · United States.
Among the 59 studies in Ileus with a site in United States, this one is the 41st largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 2, and was the 9th registered.
167 studies on the registry are indexed under Ileus; 23 are open to participants now.
Browse Ileus studies →4 of the 59 studies in Ileus with a site in United States are open now. Recruiting first, the newest first:
Casey Morehouse, DO · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
Stefan Holubar MD MS FACS, FASCRS · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Ileus studies recruiting now, 12 (63%) set no upper age limit and 4 (21%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 12 · Phase 4 7
First in 2001; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 90 across 138 interventional studies indexed under Ileus.
Median enrollment 80 across the 53 interventional studies, 150 across the 6 observational. Of the 48 that completed or were terminated, 22 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 59 have an industry lead sponsor. The 10 most frequent:
Tioga Pharmaceuticals is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Tioga Pharmaceuticals has 1 study filed under Ileus — fewer than ten, so there is no comparison to draw.
2 of the studies in Ileus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05344417Ohio State UniversityLow Pressure Pneumoperitoneum and Postoperative Ileus | 2026-12-30 |
| NCT07574437The Cleveland ClinicAt-Home Bowel Stimulation | 2027-07-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Ileus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of asimadoline in patients who have undergone a laparoscopic segmental colectomy and determine whether it reduces the time to recovery of bowel function compared to placebo.
This randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of two dose levels of asimadoline on the duration of post-operative ileus in subjects undergoing laparoscopic or hand-assisted laparoscopic colon resections. Subjects meeting entry criteria were randomized in a 1:1:1 ratio to receive either asimadoline 1.0 mg, asimadoline 3.0 mg or a placebo. One hundred and fourteen subjects were planned, and in the event that a subject was converted from a laparoscopic surgery to an open surgery (laparotomy), that subject would be discontinued from the trial and followed for safety only. The protocol allowed subjects converted to open procedures to be replaced. The first dose was administered approximately 90 minutes pre-operatively, and subsequent dosing was b.i.d. for up to 10 post-operative doses. Subjects were dosed with study drug only while in the hospital. After discharge, they were followed for an additional 28 days. Total study duration for each patient was approximately 5 to 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Asimadoline 1.0 mg b.i.d.
Drug: Asimadoline
Asimadoline 3.0 mg b.i.d.
Drug: Asimadoline
Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
Also known as: EMD 61 753, EMR 63 320
Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
Time to Return of Upper and Lower GI Function
The time to first bowel movement or the time to tolerating solid food, whichever occurs later.
Time frame: Daily for 38 days
Time to Tolerating Solid Food
Time to tolerating solid food (toleration is defined as the absence of nausea or vomiting) within 4 hours of ingesting a meal
Time frame: 4 hours of ingesting a meal
Time to First Passage of Flatus
Time frame: Daily for 38 days
Time to First Bowel Movement
Time frame: Daily for 38 days
Time to Writing of Hospital Discharge Order
Time frame: Daily for 38 days
Nausea Score
Time frame: Daily for 38 days
Vomiting Score
Time frame: Daily for 38 days
Pain Score
Time frame: Daily for 38 days
Nasogastric Tube Re-insertion
Proportion of subjects with nasogastric tube re-insertion
Time frame: Daily for 38 days
Post-operative Analgesic Use
Time frame: Daily for 38 days
Adverse Events
Adverse events grouped by body system
Time frame: Daily for 38 days
Laboratory Values
Changes in laboratory values.
Time frame: Daily for 38 days
| Milestone | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo |
|---|---|---|---|
| Started | 14 | 11 | 10 |
| Completed | 10 | 11 | 9 |
| Not completed | 4 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Converted to an open laparotomy | 3 | 0 | 1 |
Time to tolerating solid food (toleration is defined as the absence of nausea or vomiting) within 4 hours of ingesting a meal
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
The time to first bowel movement or the time to tolerating solid food, whichever occurs later.
No measurements were reported for this outcome.
Proportion of subjects with nasogastric tube re-insertion
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Adverse events grouped by body system
Results for this outcome have not been posted.
Changes in laboratory values.
Results for this outcome have not been posted.
Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asimadoline 1.0 mg | — | 0/14 (0%) | 14/14 (100%) |
| Asimadoline 3.0 mg | — | 1/11 (9.1%) | 11/11 (100%) |
| Placebo | — | 1/10 (10%) | 10/10 (100%) |
| Event | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo |
|---|---|---|---|
| bleeding gastric ulcerGastrointestinal disorders | 0/14 | 0/11 | 1/10 |
| omental necrosisGastrointestinal disorders | 0/14 | 1/11 | 0/10 |
| Event | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 5/14 | 7/11 | 4/10 |
| Procedural PainInjury, poisoning and procedural complications | 4/14 | 5/11 | 6/10 |
| Abdominal PainGastrointestinal disorders | 6/14 | 5/11 | 3/10 |
| VomitingGastrointestinal disorders | 1/14 | 4/11 | 0/10 |
| Abdominal DistensionGastrointestinal disorders | 4/14 | 1/11 | 0/10 |
| Incision Site PainInjury, poisoning and procedural complications | 3/14 | 0/11 | 1/10 |
| HeadacheNervous system disorders | 2/14 | 2/11 | 1/10 |
| Wound InfectionInfections and infestations | 1/14 | 2/11 | 1/10 |
| AnaemiaBlood and lymphatic system disorders | 0/14 | 2/11 | 0/10 |
| DizzinessNervous system disorders | 0/14 | 2/11 | 0/10 |
| Age, Categorical(Participants) | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 6 | 6 | 22 |
| >=65 years | 4 | 5 | 4 | 13 |
| Age Continuous(years) | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 58 ± 9.7 | 60 ± 12.9 | 57 ± 15.3 | 58 ± 12.2 |
| Sex: Female, Male(Participants) | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 7 | 3 | 15 |
| Male | 9 | 4 | 7 | 20 |
| Region of Enrollment(participants) | Asimadoline 1.0 mg | Asimadoline 3.0 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 14 | 11 | 10 | 35 |
The record gives a start of Jan 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 3 years 11 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asimadoline
Tioga Pharmaceuticals